FIGURE 5.

Q8 has additive antiangiogenic effects with an anti-VEGF biologic, bevacizumab. A, HMEC-1 endothelial cell tubule formation was significantly reduced following 16-h treatment with analogue Q8 in combination with bevacizumab compared with treatment with Q8 or bevacizumab alone. Q1 did not significantly reduce tubule formation in combination with bevacizumab compared with treatment with quininib or bevacizumab alone. 7,500 cells were seeded in μ-Slide angiogenesis wells and treated in duplicate for each individual experiment, and individual experiments were conducted three times (n = 3). B, representative tubule images of HMEC-1 endothelial cells treated with analogue Q8 or Q1 alone or in combination with bevacizumab for 16 h. Statistical analysis was performed by ANOVA and Dunnett's or Bonferroni's post hoc multiple comparison test and Student's t test. Error bars are mean ± S.E. *, p < 0.05; **, p < 0.01; ns, not significant.